EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access

Association of psychiatric and substance use disorders with cannabis use and cannabis use disorder during early pregnancy in northern California

Kelly C Young-Wolff iD, Felicia W Chi, Cynthia I Campbell, Monique B Does, Qiana L Brown iD, Stacey E Alexeeff, Deborah Ansley, Xiaoming Wang, Gwen T Lapham iD

Addiction · 2024

DOI: 10.1111/add.16622 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Addiction, 2024. Verfasst von Kelly C Young-Wolff und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA. Hauptthemen laut MEDLINE: Substance-Related Disorders, Marijuana Abuse, Mental Disorders, Marijuana Use. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDA NIH HHS, NIDA Clinical Trials Network, National Institute on Drug Abuse.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To estimate the strength of association between psychiatric disorders and substance use disorders (SUD), and cannabis use and cannabis use disorder (CUD) during early pregnancy.

Design

Observational study.

Setting

Kaiser Permanente Northern California, USA.

Participants

299 496 pregnancies from 227 555 individuals screened for cannabis use by self‐report and a urine toxicology test at entrance to prenatal care in Kaiser Permanente Northern California during January 2011–December 2021 (excepting year 2020). The sample was 62.5% non‐White, with a mean (standard deviation) age of 31.1 (5.5) years; 6.8% used cannabis; 0.2% had a CUD.

Measurements

Exposure variables included electronic health record‐based psychiatric diagnoses of attention deficit hyperactivity, anxiety, bipolar, depressive, personality, posttraumatic stress and psychotic disorders; and alcohol, opioid, stimulant and tobacco use disorders, during the two years prior to pregnancy up to the day before the prenatal substance use screening date. Outcome variables were any cannabis use, frequency of self‐reported cannabis use and CUD during early pregnancy.

Findings

Psychiatric disorder prevalence ranged from 0.2% (psychotic) to 14.3% (anxiety), and SUD ranged from 0.3% (stimulant/opioid) to 3.8% (tobacco). Psychiatric disorders were associated with cannabis use and CUD, with the strongest association for any use found for bipolar disorder (adjusted odds ratio [aOR] = 2.83; 95% confidence interval [CI] = 2.53–3.17) and the strongest association for CUD found for psychotic disorders (aOR = 10.01, 95% CI = 6.52–15.37). SUDs were associated with cannabis use and CUD, with the strongest association for any use found for tobacco use disorder (aOR = 4.03, 95% CI = 3.82–4.24) and the strongest association for CUD found for stimulant use disorder (aOR = 21.99, 95% CI = 16.53–29.26). Anxiety, bipolar, depressive disorders and tobacco use disorder were associated with greater odds of daily than monthly or less cannabis use.

Conclusions

Psychiatric disorders and substance use disorders appear to be associated with elevated odds of any and frequent cannabis use as well as cannabis use disorder during early pregnancy. In most cases, the associations with cannabis outcomes were stronger for substance use disorders than other psychiatric disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Substance-Related DisordersMarijuana AbuseMental DisordersMarijuana UsePregnancy ComplicationsHumansFemalePregnancyAdultCaliforniaAnxiety DisordersStress Disorders, Post-TraumaticPsychotic DisordersAttention Deficit Disorder with HyperactivityBipolar DisorderDepressive DisorderTobacco Use DisorderYoung Adult

Stichwörter der Autor:innen

cannabismarijuanapregnancyprenatalpsychiatric disorderssubstance use disorders

Autor:innen und Institutionen

  • Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA.
  • Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, CA, USA.
  • School of Social Work, Rutgers, The State University of New Jersey, New Brunswick, NJ, USA.
  • Regional Offices, Kaiser Permanente Northern California, Oakland, CA, USA.
  • Center of Clinical Trials Network, National Institute on Drug Abuse, NIH, Bethesda, MD, USA.
  • Health Research Institute, Kaiser Permanente Washington, Seattle, WA, USA.

ORCID-Profile: Kelly C Young-Wolff, Qiana L Brown, Gwen T Lapham

Förderung

  • NIDA NIH HHS
  • NIDA Clinical Trials Network
  • National Institute on Drug Abuse
  • National Drug Abuse Treatment Clinical Trials Network

Zitieren

APA

Young-Wolff, K. C., Chi, F. W., Campbell, C. I., Does, M. B., Brown, Q. L., Alexeeff, S. E., Ansley, D., Wang, X., & Lapham, G. T. (2024). Association of psychiatric and substance use disorders with cannabis use and cannabis use disorder during early pregnancy in northern California. Addiction. https://doi.org/10.1111/add.16622

Vancouver

Young-Wolff KC, Chi FW, Campbell CI, Does MB, Brown QL, Alexeeff SE, et al. Association of psychiatric and substance use disorders with cannabis use and cannabis use disorder during early pregnancy in northern California. Addiction. 2024. doi:10.1111/add.16622

BibTeX
@article{YoungWolff2024,
  author = {Young-Wolff, Kelly C and Chi, Felicia W and Campbell, Cynthia I and Does, Monique B and Brown, Qiana L and Alexeeff, Stacey E and Ansley, Deborah and Wang, Xiaoming and Lapham, Gwen T},
  title = {Association of psychiatric and substance use disorders with cannabis use and cannabis use disorder during early pregnancy in northern California},
  journal = {Addiction},
  year = {2024},
  doi = {10.1111/add.16622}
}
Kostenlos starten →